Long-Term Efficacy and Safety of Single-Agent Ibrutinib at 3 Years Follow-up in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL)

S206 (21%) and 17pdel in 8 (12.9%) cases. The median time to first treatment was 22.8 months. We analyzed OS using 20 months as an arbitrary set point to stratify patients based on our calculated median time to treatment. The median OS for patients requiring treatment before 20 months vs. patients treated after 20 months were 7.8 and 12.1 years, respectively (p1⁄40.014). Chi square analysis revealed that NOTCH1 and trisomy 12 were associated with patients requiring treatment before 20 months (p1⁄40.028 and p1⁄40.015, respectively). There was no correlation among TP53 mutation (p1⁄40.52) and 17p deletion (p1⁄40.522) with requiring early treatment. Median OS of patients with mutated NOTCH1 vs. wild type NOTCH1 was 11 years and 15.7 years, respectively (p1⁄40.334). Conclusion: In our study, we showed the association of NOTCH1 mutations with earlier need for treatment (<20 months) and that time to first treatment did correlate with a statistically significant 35.5% reduction in OS. Independent of time to treatment, patients with mutated NOTCH1 had a shorter median OS; however this was not statistically significant. Prospective studies will be important to determine the impact of NOTCH1 in patients with high-risk CLL.